Global Healthcare Company Faces Drug Diversion Allegations

We represented a global healthcare company regarding a drug diversion allegation that controlled substances were inappropriately ordered, secured and dispensed by the company in violation of state and federal law. After conducting an internal investigation into the allegations and meeting with the DEA, the government declined to pursue further action against our client.

You Also May Be Interested In:

  • Obtained a jury trial victory on six of seven counts for the former vice president of Pilot Flying J who, along with three others, was accused of seeking to defraud customers

    Bass, Berry & Sims obtained a jury trial victory on six of seven counts for the former vice president of...
  • Successful representation of a public company in an 18-month Securities & Exchange Commission (SEC) investigation related to accounting and disclosure issues, resulting in a decision by the SEC to terminate the investigation

    We successfully represented a public company in an 18-month Securities & Exchange Commission (SEC) investigation related to accounting and disclosure...
    Client Type: Public Company
  • Represented a large hospital system and negotiated a favorable settlement with HHS-OIG utilizing the OIG’s Self-Disclosure Protocol.  More specifically, our team conducted an internal investigation into possible compliance issues, drafted the disclosure for provision to HHS-OIG, and negotiated the final settlement between the parties resulting in a favorable resolution for the hospital.

    We represented a large hospital system and negotiated a favorable settlement with HHS-OIG utilizing the OIG's Self-Disclosure Protocol.  More specifically,...
    Client Type: Nonprofit